Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Biogen Inc. has received an average rating of "Hold" from 31 analysts, with 20 recommending hold and 11 giving a buy rating, while the average target price is set at $180.69.
• Despite a recent 0.1% decline in shares, Biogen reported earnings of $5.47 per share, surpassing estimates and showing a 7.3% increase in revenue year-over-year.
• Insider Priya Singhal sold 517 shares at $133.55, which represents an 8.22% decrease in her position, highlighting potential insider trading activity amidst general market trends.

Shares of Biogen Inc. (NASDAQ:BIIB - Get Free Report) have earned an average rating of "Hold" from the thirty-one analysts that are currently covering the company, Marketbeat.com reports. Twenty analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $180.6923.

BIIB has been the topic of several research analyst reports. Rothschild & Co Redburn boosted their target price on Biogen from $149.00 to $150.00 and gave the stock a "neutral" rating in a research note on Monday, October 6th. Jefferies Financial Group assumed coverage on shares of Biogen in a research note on Thursday, September 25th. They set a "buy" rating and a $190.00 price objective for the company. Wall Street Zen upgraded shares of Biogen from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 28th. Truist Financial assumed coverage on shares of Biogen in a research note on Monday, July 21st. They set a "hold" rating and a $142.00 price objective for the company. Finally, HC Wainwright lifted their price objective on shares of Biogen from $187.00 to $194.00 and gave the stock a "buy" rating in a research note on Friday, August 1st.

Biogen Stock Down 0.1%

Shares of BIIB stock opened at $149.89 on Friday. Biogen has a 1-year low of $110.04 and a 1-year high of $187.58. The stock's fifty day moving average price is $143.03 and its 200 day moving average price is $132.27. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.50 and a quick ratio of 1.79. The company has a market cap of $21.98 billion, a price-to-earnings ratio of 14.33, a price-to-earnings-growth ratio of 1.19 and a beta of 0.13.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, topping the consensus estimate of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The firm had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.32 billion. During the same period in the previous year, the business earned $5.28 EPS. The firm's revenue for the quarter was up 7.3% on a year-over-year basis. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS. On average, research analysts expect that Biogen will post 15.83 earnings per share for the current fiscal year.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 517 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total transaction of $69,045.35. Following the completion of the transaction, the insider directly owned 5,772 shares of the company's stock, valued at approximately $770,850.60. This trade represents a 8.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.18% of the company's stock.

Hedge Funds Weigh In On Biogen

A number of institutional investors have recently bought and sold shares of the business. Citizens Financial Group Inc. RI raised its position in Biogen by 11.5% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 1,997 shares of the biotechnology company's stock worth $280,000 after buying an additional 206 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in Biogen during the third quarter worth about $60,000. Philip James Wealth Mangement LLC acquired a new stake in Biogen during the third quarter worth about $301,000. ORG Wealth Partners LLC acquired a new stake in Biogen during the third quarter worth about $49,000. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in Biogen by 10.6% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 20,021 shares of the biotechnology company's stock worth $2,805,000 after acquiring an additional 1,918 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.